Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 98420X202 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Morgan Stanley
13G/A
|
10.2% |
3/6/2026
Event 2/28/2026
|
||
| Morgan Stanley | 10.2% | |||
| Morgan Stanley Investment Management Inc. | 10.2% | |||
| Inception Trust | 5.2% | |||
|
Empery Asset Management, LP
13G/A
|
10.0% |
1/15/2026
Event 12/31/2025
|
||
| Empery Asset Management, LP | 10.0% | |||
| Ryan M. Lane | 10.0% | |||
|
Coastlands Capital LP
13G
|
10.0% |
10/3/2025
Event 10/3/2025
|
||
| Coastlands Capital LP | 10.0% | |||
| Coastlands Capital Partners LP | 10.0% | |||
| Coastlands Capital GP LLC | 10.0% | |||
| Coastlands Capital LLC | 10.0% | |||
| Matthew D. Perry | 10.0% | |||
|
Deep Track Capital, LP
13G/A
|
8.3% |
8/14/2026
Event 6/30/2026
|
||
| Deep Track Capital, LP | 8.3% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 7.2% | |||
| David Kroin | 8.3% | |||
| Deep Track Special Opportunities Fund, LP. | 1.2% | |||
|
Perceptive Advisors LLC
13G/A
|
8.1% |
8/14/2026
Event 6/30/2026
|
||
| Perceptive Advisors LLC | 8.1% | |||
| Joseph Edelman | 8.1% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 8.1% | |||
|
Bain Capital Life Sciences Fund, L.P.
13G/A
|
7.4% |
2/17/2026
Event 12/31/2025
|
||
| Bain Capital Life Sciences Fund, L.P. | 0% | |||
| Bain Capital Life Sciences Fund II, L.P. | 0.1% | |||
| BCIP Life Sciences Associates, LP | <0.1% | |||
| BCLS II Investco, LP | 0.8% | |||
| BCLS I Investco, LP | 0.1% | |||
| BCLS II Equity Opportunities, LP | 7.4% | |||
|
Saturn V Capital Management LP
13G
|
7.4% |
2/17/2026
Event 10/24/2025
|
||
| Saturn V Capital Management LP | 7.4% | |||
| Xiaoying Tian | 7.4% | |||
|
Growth Equity Opportunities 18 VGE, LLC
13D/A
|
6.2% |
10/29/2025
Event 10/27/2025
|
||
| Growth Equity Opportunities 18 VGE, LLC | 6.2% | |||
| NEA 18 Venture Growth Equity, L.P. | 6.2% | |||
| NEA Partners 18 VGE, L.P. | 6.2% | |||
| Nea 18 Vge GP, LLC | 6.2% | |||
| Ali Behbahani | 6.2% | |||
| Carmen Chang | 6.2% | |||
| Anthony A. Florence, Jr. | 6.2% | |||
| Mohamad H. Makhzoumi | 6.2% | |||
| Edward T. Mathers | 6.2% | |||
| Scott D. Sandell | 6.2% | |||
| Paul Walker | 6.2% | |||
| Rick Yang | 6.2% | |||
| BlackRock, Inc. 13G | 5.9% |
7/30/2026
Event 6/30/2026
|
||
|
Trails Edge Capital Partners, LP
13G/A
|
5.8% |
2/17/2026
Event 12/31/2025
|
||
| Trails Edge Capital Partners, LP | 5.8% | |||
| Trails Edge Biotechnology Master Fund, LP | 5.8% | |||
| Ortav Yehudai | 5.8% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G
|
5.6% |
9/21/2026
Event 9/14/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 5.6% | |||
| VHCP Co-Investment Holdings III, LLC | 5.6% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 5.6% | |||
| VHCP Management III, LLC | 5.6% | |||
| VHCP Management EG, LLC | 5.6% | |||
| Nimish Shah | 5.6% | |||
| Bong Y. Koh | 5.6% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
FMR LLC
13G/A
|
4.6% |
10/7/2026
Event 9/30/2026
|
||
| FMR LLC | 4.6% | |||
| Abigail P. Johnson | 4.6% | |||
|
Biotechnology Value Fund L P
13G/A
|
3.9% |
2/17/2026
Event 12/31/2025
|
||
| Biotechnology Value Fund L P | 2.1% | |||
| BVF I GP LLC | 2.1% | |||
| Biotechnology Value Fund II LP | 1.5% | |||
| BVF II GP LLC | 1.5% | |||
| Biotechnology Value Trading Fund OS LP | 0.2% | |||
| BVF Partners OS Ltd. | 0.2% | |||
| BVF GP Holdings LLC | 3.6% | |||
| BVF Partners L P/IL | 3.9% | |||
| BVF Inc/IL | 3.9% | |||
| Lampert Mark N | 3.9% | |||
|
Nantahala Capital Management, LLC
13G/A
|
2.8% |
2/13/2026
Event 12/31/2025
|
||
| Nantahala Capital Management, LLC | 2.8% | |||
| Wilmot B. Harkey | 2.8% | |||
| Daniel Mack | 2.8% | |||